Source: SEBI
What would have to hold for each case — not a price target or a projected figure. CapitSignal does not forecast where this stock trades.
The U.S. healthcare market continues to grow at projected rates.
The U.S. RCM market is expected to grow from U.S.$234.5 billion in CY25 to U.S.$329.8 billion by CY30, with AGS positioned to capture this growth.
Customer retention remains high and new customer acquisition accelerates.
AGS reported a customer retention rate of 98.81% in Fiscal 2026, indicating strong customer loyalty.
The company's financial performance follows the trajectory outlined in the prospectus.
AGS generated revenue from operations of ₹20,414.20 million in Fiscal 2026, with a consistent growth pattern over the previous years.
Operational efficiencies are maintained as the company scales.
The company has improved its employee voluntary attrition rate from 33.51% in Fiscal 2024 to 23.28% in Fiscal 2026.
Regulatory compliance issues lead to financial penalties.
The company faces risks associated with U.S. federal and state healthcare laws, which could result in financial penalties or operational changes.
Customer concentration leads to significant revenue loss.
The company is dependent on its top 10 customers, which accounted for 59.67% of revenue from operations in Fiscal 2026.